A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks
The studies needed before a first human trial cost a few million and no grant pays for them. A dedicated fund would decide in weeks and take a small share of any future revenue.
A revolving fund, capitalised by philanthropy and public money, that pays for GLP toxicology, CMC development, formulation and regulatory writing for academic oncology candidates that have passed independent replication of the key efficacy result. Decisions in eight weeks by a standing expert panel; awards of $2 to $8 million; in return the fund takes a low single-digit royalty or a share of licensing revenue, recycled into the fund. Structured like the Wellcome Trust's Seeding Drug Discovery or the Michael J. Fox Foundation's therapeutic pipeline programme, but oncology-focused and paired with the translational institutes. Most academic assets stall exactly here because IND-enabling work is neither science (so not fundable by grants) nor de-risked enough for companies.
- The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
Pages like this
not linked directly; found by shared links- IdeaGovernment reinsurance for phase 2 failures of first-in-class cancer drugs
Shares Public co-investment in first-in-class phase 1 with a royalty return, The valley of death between lab and product.
- IdeaForty-eight-hour small grants for bold experiments in neglected cancers
Shares A phase 0 fund to test academic compounds in humans with microdoses and imaging, The valley of death between lab and product.
- IdeaTwo-year translational fellowships that pay scientists to develop their own discovery
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.
- IdeaA pre-competitive consortium to validate or kill academic targets before licensing
Shares Set aside 3% of grant budgets to replicate findings before translation, The valley of death between lab and product.
- IdeaAn open engineering platform for academic ADCs and bispecifics
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.
- IdeaShared modular GMP facilities for academic personalised vaccines and cell products
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.
- IdeaA national non-profit contract research organisation for academic oncology trials
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.
- IdeaScale up public drug development that takes academic assets to phase 1
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.